Pharmacokinetics and Pharmacodynamics of Rocuronium in Closed-Loop Infusion System
NCT ID: NCT02364934
Last Updated: 2015-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
240 participants
OBSERVATIONAL
2015-03-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To discover and confirm sex differences on the pharmacokinetics and pharmacodynamics of rocuronium.
To evaluate and examine aged people on the pharmacokinetics and pharmacodynamics of rocuronium.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation
NCT07168252
Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane
NCT02711917
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
NCT05687253
THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients
NCT02111265
Dual-loop Target Controlled Infusion for Coadministration of Propofol and Remifentanil Guided by Narcotrend Index
NCT02890186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods Two hundred and ten patients, ASA physical status group I and II undergoing elective surgical procedures were studied. Pateients with neuromuscular and metabolic diseases, morbid obesity or receiving medication known to influence neuromuscular transmission were excluded from the study.
Anaesthesia Patients will be assigned at random to receive propofuol, sevolurane or propoful+sevoflurane anaesthesia. All patients will induced with midazolam, 0.1 mg/kg, sufentnail, 0.5 μg/kg, etomidate, 0.3 mg/kg and rocuronium, 0.6 mg/kg. In the propoful group, anaesthesia will be continued with propoful and sufentanil. The doseage of propotul and sufentanil will be adjusted by the blood pressure and heart rate of the patients. In the sevoflurane group, anaesthesia will be continued with sevoflurane (2%) and sufentanil. The doseage of sufentanil will be adjusted by the blood pressure and heart rate of the patients. The doseage of propoful and sufentanil will be adjusted by the blood pressure and heart rate of the patients.
Heart rate, invasive blood pressure, pulse and core body temperature were monitored throughout the procedure. The core body temperature was main tained between 36°C and 37°C using a warming blanket. Positive pressure ventilation was used to maintain the end-tidal CO2 between 4.5 kPa and 5.5 kPa. The inspired and end-tidal concentrations of carbon dioxide and volatile anaesthestics were monitored by a multigas monitor.
Neuromuscular transmission was monitored by recording the electromyographic (EMG) activity of the adductor pollicis muscle resulting from the supra- maximal stimulation of the ulnar nerve with train-of- four (TOF), 2 Hz for 2 s, applied at 10-s intervals. The ulnar nerve was stimulated through surface electrodes applied at the wrist, using square-wave currents of 0.2 ms duration. Ten minutes were allowed for the stabilization of anaesthesia and the EMG tracing before the intubating dose of rocuronium, 0.6 mg/kg, was given by the anaesthesiologist.
Rocuronium infusion A personal computer, working in a closed-loop system with the Relaxograph and a syringe infusion pump was used to administer rocuronium at the rate necessary for a stable 90-99% block of the first twitch response (1%\<T1\<10%). The infusion of rocuronium was started automatically when T1 returned to 5% of the control value. The initial infusion rate was set at 10 mg/kg/min, and subsequently adjusted by the computer. Every 10 s the computer received data (T1 value) from the Relaxograph. If T1 increased above 10%, the infusion rate was increased by 2/3. If T1 increased above 15%, a bolus dose (0.06 mg/kg) was administered automatically to avoid an undesirable return of the muscle strength during surgery. The neuromuscular block was considered stable if T1 changed by no more than 2% over a 10-min observation period. The rocuronium infusion was automatically stopped if three consecutive T1 values equalled 0. The working mode (automatic or manual), the last six T1 values and the 15-min T1 trend could be observed on screen. The anaesthesiologist could override the computer-set infusion rate at any time, by changing the working mode from automatic to manual, and stop the infusion when the surgery was completed.
All neuromuscular transmission data, as well as the data on the infusion rate during the closed-loop system feed-back infusion of the relaxant, were saved in a Microsoft Excel compatible computer file.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propofol
Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
Propofol
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Sevoflurane
Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
Sevoflurane
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Propofol (elderly)
Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
Propofol
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Sevoflurane (elderly)
Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
Sevoflurane
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Propofol (men)
Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
Propofol
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Sevoflurane (men)
Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
Sevoflurane
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Propofol (women)
Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
Propofol
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Sevoflurane (women)
Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
Sevoflurane
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propofol
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Sevoflurane
This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* elective surgical procedures
* The subject has given written informed consent to participate
Exclusion Criteria
* Severe HBP, obesity (BMI\>30)
* Neuromuscular and metabolic diseases
* Receiving medication known to influence neuromuscular transmission
* Pregnancy, psychiatric disease
* Allergy history
* Inability to understand the Study Information Sheet and provide a written consent to take part in the study.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Donglai Yan
Chief
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB014-090-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.